Familial Hypercholesterolemia in Turkey (A-HIT2)

NCT03110250 | Completed DMC

• 1 other identifier: A-HIT2
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

A-HIT2, is also designed as a National FH registry. At least 1000 FH patients will be recruited from 30 outpatient clinics representing the 12 Nuts statistical Regions in Turkey proportional to the 2015 Turkey's Population distribution.\[14\] Both HeFH and HoFH patients are eligible for enrollment. Sites specialized on cardiology, internal medicine, and endocrinology were invited by the Turkish Society of Cardiology.

Conditions

Familial Hypercholesterolemia; Atherosclerosis

Keywords

Familial Hypercholesterolemia; registry; Turkey; Lipid lowering therapy

Outcome Measures

Primary Outcomes (1)

• number of patients receiving proper treatment for FH

  how many patients are receieving the proper lipid lowering drugs for the diagnosis of FH

  February- November 2017

Secondary Outcomes (1)

• number of patients reaching LDL-cholesterol goal according to risk status (risk level)

  February- November 2017

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

At least 1000 Familial Hypercholesterolemia (FH) patients are being recruited from 30 outpatient clinics representing the 12 Nuts statistical Regions in Turkey proportional to the 2015 Turkey's Population distribution. Both HeFH and HoFH patients are eligible for enrollment. Sites specialized on cardiology, internal medicine, and endocrinology were invited by the Turkish Society of Cardiology.

You may qualify if:

• age \> 18 years and being diagnosed as possible FH.
• The possible FH was defined as having a total score of \> 2 according to Dutch lipid clinic network (DLCN) criteria

You may not qualify if:

• Patients with triglyceride levels \> 400 mg/dl or secondary hyperlipidemia (ie, untreated hypothyroidism, nephrotic syndrome, cholestasis, etc..) will be excluded from the study.

Sponsors & Collaborators

• Ege University: lead
• Turkish Society of Cardiology: collaborator

Study Sites (1)

Ege University Medical School

Izmir, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Hyperlipoproteinemia Type II; Atherosclerosis

Condition Hierarchy (Ancestors)

Lipid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hyperlipoproteinemias; Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Meral Kayikcioglu

  Ege University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor MD

Study Record Dates

• First Submitted: April 3, 2017
• First Posted: April 12, 2017
• Study Start: February 26, 2017
• Primary Completion: November 30, 2017
• Study Completion: December 5, 2017
• Last Updated: December 7, 2017

Record last verified: 2017-12

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)